← Back

Christiani & Nielsen (Thai) Public Company Limited

Christiani & Nielsen (Thai) Public Company Limited, together with its subsidiaries, provides construction services for government and private sectors. It operates in two segments Construction services, and Sales and Service. The company engages in the civil and infrastructure; general buildings and hospitality; power and petrochemicals; and industrial facilities and hypermarkets business, as well as property development business. It also provides services for energy solutions in solar, wind, and other renewable energy sectors; and develops renewable energy-based power producing facilities. The company was formerly known as Christiani & Nielsen (Siam) Ltd. and changed its name to Christiani & Nielsen (Thai) Public Company Limited in November 1992. The company was founded in 1904 and is headquartered in Bangkok, Thailand. Christiani & Nielsen (Thai) Public Company Limited operates as a subsidiary of Globex Corporation Limited.

Price · split & dividend adjusted
News & notes moving CNT.BK
CNT.BK

Dark horse stocks surge with strong profits as several companies post standout results

Several mid- and small-cap stocks reported standout profit growth for the second quarter of 2026. TITLE posted a profit of 251 million baht, up 32-fold, driven by the transfer of three major Phuket condominium projects, bringing first-half profit to nearly 293 million baht. CNT reported a profit of 159 million baht, up more than 1,900 percent, thanks to large construction projects and data center work. TKS posted a profit of 168 million baht, up 1,311 percent, boosted by share of profit from associates and its IT ecosystem portfolio. STGT reported first-half profit of 950 million baht, supported by a recovery in rubber gloves and higher margins. PAP posted first-half profit of 425 million baht and will pay a dividend of 9 satang per share. INSET has a backlog of more than 5.8 billion baht and is bidding for nine new projects worth over 5 billion baht. BKGI expects 2026 growth of up to 30 percent, driven by its cancer diagnostics business and government policies supporting genomic medicine.
Kaohoon·7dRead more ▾